{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:25:59Z","timestamp":1778343959550,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016565","name":"UAE","doi-asserted-by":"publisher","award":["# 1701050126-P"],"award-info":[{"award-number":["# 1701050126-P"]}],"id":[{"id":"10.13039\/100016565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016565","name":"UAE","doi-asserted-by":"publisher","award":["# 2001090176"],"award-info":[{"award-number":["# 2001090176"]}],"id":[{"id":"10.13039\/100016565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["# 120301"],"award-info":[{"award-number":["# 120301"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.dsx.2020.10.028","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T23:48:48Z","timestamp":1604101728000},"page":"2087-2092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5416-8691","authenticated-orcid":false,"given":"Samir","family":"Awadallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal","family":"Taneera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Khader","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Unnikannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2020.10.028_bib1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.dsx.2020.10.028_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.dsx.2020.10.028_bib3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"Journal of lipid research"},{"key":"10.1016\/j.dsx.2020.10.028_bib4","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dsx.2020.10.028_bib5","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dsx.2020.10.028_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.dsx.2020.10.028_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2020.10.028_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cca.2014.10.044","article-title":"PCSK9 and its modulation","volume":"440","author":"Cui","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dsx.2020.10.028_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.dsx.2020.10.028_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.dsx.2020.10.028_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.arteri.2015.11.001","article-title":"Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders","volume":"28","author":"Ibarretxe","year":"2016","journal-title":"Cl\u00edn Invest Arterioscler"},{"key":"10.1016\/j.dsx.2020.10.028_bib13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jdiacomp.2015.08.003","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 is associated with Lp (a) in type 2 diabetic patients","volume":"29","author":"Nekaies","year":"2015","journal-title":"J\u00a0Diabetes Complicat"},{"key":"10.1016\/j.dsx.2020.10.028_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12944-018-0658-z","article-title":"Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population","volume":"17","author":"Guo","year":"2018","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.dsx.2020.10.028_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/pedi.12490","article-title":"Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women","volume":"18","author":"Levenson","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.dsx.2020.10.028_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.atherosclerosis.2011.03.023","volume":"217","author":"Brouwers","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"Journal of lipid research"},{"key":"10.1016\/j.dsx.2020.10.028_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","article-title":"PCSK9 and lipid lowering drugs","volume":"437","author":"Guo","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dsx.2020.10.028_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","article-title":"PCSK9 and diabetes: is there a link?","volume":"22","author":"Momtazi","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.dsx.2020.10.028_bib20","first-page":"RV17012","article-title":"Lipid lowering therapy and circulating PCSK9 concentration","author":"Nozue","year":"2017","journal-title":"J\u00a0Atherosclerosis Thromb"},{"key":"10.1016\/j.dsx.2020.10.028_bib21","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1074\/jbc.M508582200","article-title":"Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c","volume":"281","author":"Costet","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dsx.2020.10.028_bib22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/ATVBAHA.115.305688","article-title":"Role of insulin in the regulation of proprotein convertase subtilisin\/kexin type 9","volume":"35","author":"Miao","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2020.10.028_bib23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.clinbiochem.2014.03.022","article-title":"The effect of insulin on circulating PCSK9 in postmenopausal obese women","volume":"47","author":"Awan","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.dsx.2020.10.028_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.dsx.2020.10.028_bib25","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.5114\/amsad.2019.86752","article-title":"Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?","volume":"4","author":"Shek","year":"2019","journal-title":"Archives of medical sciences Atherosclerotic diseases"},{"key":"10.1016\/j.dsx.2020.10.028_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031969","article-title":"Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study","volume":"9","author":"Mahmoud","year":"2019","journal-title":"BMJ open"},{"key":"10.1016\/j.dsx.2020.10.028_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13098-017-0287-0","article-title":"Prevalence of overweight and obesity in United Arab Emirates Expatriates: the UAE national diabetes and lifestyle study","volume":"9","author":"Sulaiman","year":"2017","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.dsx.2020.10.028_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5551\/jat.12.295","article-title":"The metabolic syndrome: a global public health problem and a new definition","volume":"12","author":"Zimmet","year":"2005","journal-title":"J\u00a0Atherosclerosis Thromb"},{"key":"10.1016\/j.dsx.2020.10.028_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.atherosclerosis.2010.04.015","article-title":"Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients","volume":"211","author":"Cariou","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.numecd.2019.04.006","article-title":"Association of serum proprotein convertase subtilisin\/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus","volume":"29","author":"Guo","year":"2019","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.dsx.2020.10.028_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.dsx.2020.10.028_bib32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","article-title":"Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials","volume":"17","author":"Sahebkar","year":"2015","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2020.10.028_bib33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.dsx.2020.10.028_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2011.07.098","article-title":"Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes","volume":"219","author":"Verg\u00e8s","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2018.11.020","article-title":"Association between proprotein convertase subtilisin\/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: effects of glycemic control","volume":"280","author":"Bojanin","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/dom.12819","article-title":"Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes","volume":"19","author":"Laugier-Robiolle","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2020.10.028_bib37","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.2337\/dc16-2563","article-title":"PCSK9 is increased in youth with type 1 diabetes","volume":"40","author":"Levenson","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2020.10.028_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/dmrr.2712","article-title":"Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes","volume":"32","author":"Yang","year":"2016","journal-title":"Diabetes\/metabolism research and reviews"},{"key":"10.1016\/j.dsx.2020.10.028_bib39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2010.10.028","article-title":"Plasma proprotein convertase subtilisin\u2013kexin type 9 does not change during 24 h insulin infusion in healthy subjects and type 2 diabetic patients","volume":"214","author":"Kappelle","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib40","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.dsx.2017.03.012","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females","volume":"11","author":"Hasan","year":"2017","journal-title":"Diabetes & Metabolic Syndrome: Clin Res Rev"},{"key":"10.1016\/j.dsx.2020.10.028_bib41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","article-title":"Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients","volume":"212","author":"Costet","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.dsx.2020.10.028_bib42","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dsx.2020.10.028_bib43","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci Unit States Am"},{"key":"10.1016\/j.dsx.2020.10.028_bib44","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"Journal of lipid research"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120304598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402120304598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:18:27Z","timestamp":1761729507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402120304598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1871402120304598"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2020.10.028","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined intake of glucose-and lipid-lowering medications further elevates plasma levels of PCSK9 in type 2 diabetes patients","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2020.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}